Hellman K, Ohlsson J, Malo M, Olsson R, Ek F. Discovery of Procognitive Antipsychotics by Combining Muscarinic M1 Receptor Structure-Activity Relationship with Systems Response Profiles in Zebrafish Larvae. ACS Chem Neurosci. 2020;11:173-183 pubmed publisher

Liu Z, Jiang X, Gao L, Liu X, Li J, Huang X, et al. Synergistic Suppression of Glioblastoma Cell Growth by Combined Application of Temozolomide and Dopamine D2 Receptor Antagonists. World Neurosurg. 2019;: pubmed publisher

Zheng L, Yang L, Zhao X, Long N, Li P, Wang Y. Effect of risperidone on proliferation and apoptosis of MC3T3-E1 cells. Braz J Med Biol Res. 2019;52:e8098 pubmed publisher

Feiner B, Chase K, Melbourne J, Rosen C, Sharma R. Risperidone effects on heterochromatin: the role of kinase signaling. Clin Exp Immunol. 2019;196:67-75 pubmed publisher

Burrows E, Laskaris L, Koyama L, Churilov L, Bornstein J, Hill Yardin E, et al. A neuroligin-3 mutation implicated in autism causes abnormal aggression and increases repetitive behavior in mice. Mol Autism. 2015;6:62 pubmed publisher

Vaisburd S, Shemer Z, Yeheskel A, Giladi E, Gozes I. Risperidone and NAP protect cognition and normalize gene expression in a schizophrenia mouse model. Sci Rep. 2015;5:16300 pubmed publisher

Wang Z, Zhan Y, Li Y, Yang C, Cai J, Dai D, et al. Effects of 24 CYP2D6 Variants Found in the Chinese Population on the Metabolism of Risperidone. Pharmacology. 2015;96:290-5 pubmed publisher

Canfrán Duque A, Pastor O, Reina M, Lerma M, Cruz Jentoft A, Lasunción M, et al. Curcumin Mitigates the Intracellular Lipid Deposit Induced by Antipsychotics In Vitro. PLoS ONE. 2015;10:e0141829 pubmed publisher

Kamińska K, Rogóż Z. The effect of combined treatment with risperidone and antidepressants on the MK-801-induced deficits in the social interaction test in rats. Pharmacol Rep. 2015;67:1183-7 pubmed publisher

Shen J, Choi S, Qu W, Wang Y, Burgess D. In vitro-in vivo correlation of parenteral risperidone polymeric microspheres. J Control Release. 2015;218:2-12 pubmed publisher

Deiana S, Watanabe A, Yamasaki Y, Amada N, Kikuchi T, Stott C, et al. MK-801-induced deficits in social recognition in rats: reversal by aripiprazole, but not olanzapine, risperidone, or cannabidiol. Behav Pharmacol. 2015;26:748-65 pubmed publisher

Du X, Zhang G, Yang Y, Li Z, Pan W, Yin G, et al. Follow-up of N400 in the Rehabilitation of First-episode Schizophrenia. Chin Med J (Engl). 2015;128:2215-9 pubmed publisher

Aman M, Rettiganti M, Nagaraja H, Hollway J, McCracken J, McDougle C, et al. Tolerability, Safety, and Benefits of Risperidone in Children and Adolescents with Autism: 21-Month Follow-up After 8-Week Placebo-Controlled Trial. J Child Adolesc Psychopharmacol. 2015;25:482-93 pubmed publisher

Masi G, Milone A, Stawinoga A, Veltri S, Pisano S. Efficacy and Safety of Risperidone and Quetiapine in Adolescents With Bipolar II Disorder Comorbid With Conduct Disorder. J Clin Psychopharmacol. 2015;35:587-90 pubmed publisher

Đorđević S, Cekić N, Savić M, Isailović T, Ranđelović D, Marković B, et al. Parenteral nanoemulsions as promising carriers for brain delivery of risperidone: Design, characterization and in vivo pharmacokinetic evaluation. Int J Pharm. 2015;493:40-54 pubmed publisher

Ghaleiha A, Rasa S, Nikoo M, Farokhnia M, Mohammadi M, Akhondzadeh S. A pilot double-blind placebo-controlled trial of pioglitazone as adjunctive treatment to risperidone: Effects on aberrant behavior in children with autism. Psychiatry Res. 2015;229:181-7 pubmed publisher

Siafaka P, Barmpalexis P, Lazaridou M, Papageorgiou G, Koutris E, Karavas E, et al. Controlled release formulations of risperidone antipsychotic drug in novel aliphatic polyester carriers: Data analysis and modelling. Eur J Pharm Biopharm. 2015;94:473-84 pubmed publisher

Angelini A, Ciofani G, Conti P. ANTIPSYCHOTICS REVERSE P-GLYCOPROTEIN-MEDIATED DOXORUBICIN RESISTANCE IN HUMAN UTERINE SARCOMA MES-SA/Dx5 CELLS: A NOVEL APPROACH TO CANCER CHEMOTHERAPY. J Biol Regul Homeost Agents. 2015;29:357-65 pubmed

Reuss B, Schroten H, Ishikawa H, Asif A. Cross-reactivity of Antibodies Directed to the Gram-Negative Bacterium Neisseria gonorrhoeae With Heat Shock Protein 60 and ATP-Binding Protein Correlates to Reduced Mitochondrial Activity in HIBCPP Choroid Plexus Papilloma Cells. J Mol Neurosci. 2015;57:123-38 pubmed publisher

Jones P, Hewitt M, Campbell J, Quinton M, Engel S, Lew R, et al. Pharmacological evaluation of a novel phosphodiesterase 10A inhibitor in models of antipsychotic activity and cognition. Pharmacol Biochem Behav. 2015;135:46-52 pubmed publisher

Torres Lista V, López Pousa S, Giménez Llort L. Marble-burying is enhanced in 3xTg-AD mice, can be reversed by risperidone and it is modulable by handling. Behav Processes. 2015;116:69-74 pubmed publisher

Hasebe S, Ago Y, Nishiyama S, Oka S, Hashimoto H, Takuma K, et al. Pharmacological profile of encounter-induced hyperactivity in isolation-reared mice. Behav Pharmacol. 2015;26:681-90 pubmed publisher

Ortega Álvaro A, Navarrete F, Aracil Fernández A, Navarro D, Berbel P, Manzanares J. Differential Pharmacological Regulation of Sensorimotor Gating Deficit in CB1 Knockout Mice and Associated Neurochemical and Histological Alterations. Neuropsychopharmacology. 2015;40:2639-47 pubmed publisher

Bera H, Boddupalli S, Nandikonda S, Kumar S, Nayak A. Alginate gel-coated oil-entrapped alginate-tamarind gum-magnesium stearate buoyant beads of risperidone. Int J Biol Macromol. 2015;78:102-11 pubmed publisher

Baba S, Enomoto T, Horisawa T, Hashimoto T, Ono M. Blonanserin extensively occupies rat dopamine D3 receptors at antipsychotic dose range. J Pharmacol Sci. 2015;127:326-31 pubmed publisher

Elmorsy E, Smith P. Bioenergetic disruption of human micro-vascular endothelial cells by antipsychotics. Biochem Biophys Res Commun. 2015;460:857-62 pubmed publisher

Song T, Nie B, Ma E, Che J, Sun S, Wang Y, et al. Functional magnetic resonance imaging reveals abnormal brain connectivity in EGR3 gene transfected rat model of schizophrenia. Biochem Biophys Res Commun. 2015;460:678-83 pubmed publisher

Baba S, Murai T, Nakako T, Enomoto T, Ono M, Shimizu I, et al. The serotonin 5-HT₁A receptor agonist tandospirone improves executive function in common marmosets. Behav Brain Res. 2015;287:120-6 pubmed publisher

Lian J, De Santis M, He M, Deng C. Risperidone-induced weight gain and reduced locomotor activity in juvenile female rats: The role of histaminergic and NPY pathways. Pharmacol Res. 2015;95-96:20-6 pubmed publisher

Citraro R, Leo A, De Fazio P, De Sarro G, Russo E. Antidepressants but not antipsychotics have antiepileptogenic effects with limited effects on comorbid depressive-like behaviour in the WAG/Rij rat model of absence epilepsy. Br J Pharmacol. 2015;172:3177-88 pubmed publisher

Banks M, Blough B. Effects of Environmental Manipulations and Treatment with Bupropion and Risperidone on Choice between Methamphetamine and Food in Rhesus Monkeys. Neuropsychopharmacology. 2015;40:2198-206 pubmed publisher

Chen F, Gong Z, Kelly B. Rapid analysis of pharmaceuticals and personal care products in fish plasma micro-aliquots using liquid chromatography tandem mass spectrometry. J Chromatogr A. 2015;1383:104-11 pubmed publisher

Nikoo M, Radnia H, Farokhnia M, Mohammadi M, Akhondzadeh S. N-acetylcysteine as an adjunctive therapy to risperidone for treatment of irritability in autism: a randomized, double-blind, placebo-controlled clinical trial of efficacy and safety. Clin Neuropharmacol. 2015;38:11-7 pubmed publisher

Phizackerley D. Licensed indication for risperidone in dementia. BMJ. 2014;349:g7337 pubmed publisher

Okubo M, Murayama N, Miura J, Chiba Y, Yamazaki H. Effects of cytochrome P450 2D6 and 3A5 genotypes and possible coadministered medicines on the metabolic clearance of antidepressant mirtazapine in Japanese patients. Biochem Pharmacol. 2015;93:104-9 pubmed publisher

Heller H, Salehi A, Chuluun B, Das D, Lin B, Moghadam S, et al. Nest building is impaired in the Ts65Dn mouse model of Down syndrome and rescued by blocking 5HT2a receptors. Neurobiol Learn Mem. 2014;116:162-71 pubmed publisher

Dubbelman A, Cuyckens F, Dillen L, Gross G, Hankemeier T, Vreeken R. Systematic evaluation of commercially available ultra-high performance liquid chromatography columns for drug metabolite profiling: optimization of chromatographic peak capacity. J Chromatogr A. 2014;1374:122-133 pubmed publisher

Veale D, Miles S, Smallcombe N, Ghezai H, Goldacre B, Hodsoll J. Atypical antipsychotic augmentation in SSRI treatment refractory obsessive-compulsive disorder: a systematic review and meta-analysis. BMC Psychiatry. 2014;14:317 pubmed publisher

Iqbal M, Ezzeldin E, Al Rashood K, Bajrai A. A simple and fast UHPLC-MS-MS assay for rapid determination of vilazodone in plasma sample. J Anal Toxicol. 2015;39:106-12 pubmed publisher

Citraro R, Leo A, Aiello R, Pugliese M, Russo E, De Sarro G. Comparative analysis of the treatment of chronic antipsychotic drugs on epileptic susceptibility in genetically epilepsy-prone rats. Neurotherapeutics. 2015;12:250-62 pubmed publisher

Baker T, Florczynski M, Beninger R. Differential effects of clozapine, metoclopramide, haloperidol and risperidone on acquisition and performance of operant responding in rats. Psychopharmacology (Berl). 2015;232:1535-43 pubmed publisher

Hillhouse T, Shankland Z, Matazel K, Keiser A, Prus A. The quetiapine active metabolite N-desalkylquetiapine and the neurotensin NTS₁ receptor agonist PD149163 exhibit antidepressant-like effects on operant responding in male rats. Exp Clin Psychopharmacol. 2014;22:548-56 pubmed publisher

Spencer A, Uchida M, Kenworthy T, Keary C, Biederman J. Glutamatergic dysregulation in pediatric psychiatric disorders: a systematic review of the magnetic resonance spectroscopy literature. J Clin Psychiatry. 2014;75:1226-41 pubmed publisher

Sempio C, Morini L, Vignali C, Groppi A. Simple and sensitive screening and quantitative determination of 88 psychoactive drugs and their metabolites in blood through LC-MS/MS: application on postmortem samples. J Chromatogr B Analyt Technol Biomed Life Sci. 2014;970:1-7 pubmed publisher

MacMaster F, Langevin L, Jaworska N, Kemp A, Sembo M. Corpus callosal morphology in youth with bipolar depression. Bipolar Disord. 2014;16:889-93 pubmed publisher

Patteet L, Maudens K, Stove C, Lambert W, Morrens M, Sabbe B, et al. The use of dried blood spots for quantification of 15 antipsychotics and 7 metabolites with ultra-high performance liquid chromatography - tandem mass spectrometry. Drug Test Anal. 2015;7:502-11 pubmed publisher

Iqbal M, Khalil N, Imam F, Khalid Anwer M. A validated high-throughput UHPLC-MS/MS assay for accurate determination of rivaroxaban in plasma sample. J Thromb Thrombolysis. 2015;39:79-88 pubmed publisher

Pedersen C, Sørensen D, Parachikova A, Plath N. PCP-induced deficits in murine nest building activity: employment of an ethological rodent behavior to mimic negative-like symptoms of schizophrenia. Behav Brain Res. 2014;273:63-72 pubmed publisher

Freund Levi Y, Bloniecki V, Auestad B, Tysén Bäckström A, Lärksäter M, Aarsland D. Galantamine versus risperidone for agitation in people with dementia: a randomized, twelve-week, single-center study. Dement Geriatr Cogn Disord. 2014;38:234-44 pubmed publisher

Maeda K, Sugino H, Akazawa H, Amada N, Shimada J, Futamura T, et al. Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther. 2014;350:589-604 pubmed publisher

Maeda K, Lerdrup L, Sugino H, Akazawa H, Amada N, McQuade R, et al. Brexpiprazole II: antipsychotic-like and procognitive effects of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther. 2014;350:605-14 pubmed publisher

Huang Y, Pai C, Cheng K, Kuo W, Chen M, Chang K. Dopamine D(2)/D(3) receptor binding of [(123)I]epidepride in risperidone-treatment chronic MK-801-induced rat schizophrenia model using nanoSPECT/CT neuroimaging. Nucl Med Biol. 2014;41:681-7 pubmed publisher

Yeh W, Lin H, Wu H, Chen D. Combination treatment of tamoxifen with risperidone in breast cancer. PLoS ONE. 2014;9:e98805 pubmed publisher

Choi J, Widjaja F, Careaga M, Bent S, Ashwood P, Hendren R. Change in plasma cytokine levels during risperidone treatment in children with autism. J Child Adolesc Psychopharmacol. 2014;24:586-9 pubmed publisher

Waters S, Ponten H, Edling M, Svanberg B, Klamer D, Waters N. The dopaminergic stabilizers pridopidine and ordopidine enhance cortico-striatal Arc gene expression. J Neural Transm (Vienna). 2014;121:1337-47 pubmed publisher

Nagaya Y, Nozaki Y, Kobayashi K, Takenaka O, Nakatani Y, Kusano K, et al. Utility of cerebrospinal fluid drug concentration as a surrogate for unbound brain concentration in nonhuman primates. Drug Metab Pharmacokinet. 2014;29:419-26 pubmed

Dolgin E. Therapeutics: Negative feedback. Nature. 2014;508:S10-1 pubmed publisher

Li J, Zhu S, Kozono D, Ng K, Futalan D, Shen Y, et al. Genome-wide shRNA screen revealed integrated mitogenic signaling between dopamine receptor D2 (DRD2) and epidermal growth factor receptor (EGFR) in glioblastoma. Oncotarget. 2014;5:882-93 pubmed

Riga M, Soria G, Tudela R, Artigas F, Celada P. The natural hallucinogen 5-MeO-DMT, component of Ayahuasca, disrupts cortical function in rats: reversal by antipsychotic drugs. Int J Neuropsychopharmacol. 2014;17:1269-82 pubmed publisher

Piao L, Park J, Li Y, Shin S, Shin S, Kong G, et al. SOCS3 and SOCS6 are required for the risperidone-mediated inhibition of insulin and leptin signaling in neuroblastoma cells. Int J Mol Med. 2014;33:1364-70 pubmed publisher

Becker J, Clesse D, Spiegelhalter C, Schwab Y, Le Merrer J, Kieffer B. Autistic-like syndrome in mu opioid receptor null mice is relieved by facilitated mGluR4 activity. Neuropsychopharmacology. 2014;39:2049-60 pubmed publisher

Rosenheck R, Lin H. Noninferiority of perphenazine vs. three second-generation antipsychotics in chronic schizophrenia. J Nerv Ment Dis. 2014;202:18-24 pubmed publisher

Leatherman S, Liang M, Krystal J, Lew R, Valley D, Thwin S, et al. Differences in treatment effect among clinical subgroups in a randomized clinical trial of long-acting injectable risperidone and oral antipsychotics in unstable chronic schizophrenia. J Nerv Ment Dis. 2014;202:13-7 pubmed publisher

Fischer B. Schizophrenia research: where are we?. J Nerv Ment Dis. 2014;202:4-5 pubmed publisher

Glennon J, Purper Ouakil D, Bakker M, Zuddas A, Hoekstra P, Schulze U, et al. Paediatric European Risperidone Studies (PERS): context, rationale, objectives, strategy, and challenges. Eur Child Adolesc Psychiatry. 2014;23:1149-60 pubmed publisher

Amos A. Biased reporting of results in patients at ultra-high risk of psychosis. J Clin Psychiatry. 2013;74:1123 pubmed publisher

Tsermpini E, Assimakopoulos K, Bartsakoulia M, Iconomou G, Papadima E, Mitropoulos K, et al. Individualizing clozapine and risperidone treatment for schizophrenia patients. Pharmacogenomics. 2014;15:95-110 pubmed publisher

Mandpe L, Pokharkar V. Quality by design approach to understand the process of optimization of iloperidone nanostructured lipid carriers for oral bioavailability enhancement. Pharm Dev Technol. 2015;20:320-9 pubmed publisher

Kmietowicz Z. Johnson & Johnson to pay $2.2bn to settle charges of false marketing on three drugs. BMJ. 2013;347:f6696 pubmed publisher

Ersoz Alan B, Unal D. Mania after termination of epilepsy treatment: a case report. Afr J Psychiatry (Johannesbg). 2013;16:327 pubmed publisher

Batinić B, Duisin D, Barisić J. Obsessive versus delusional jealousy. Psychiatr Danub. 2013;25:334-9 pubmed

Hutchings E, Waller J, Terry A. Differential long-term effects of haloperidol and risperidone on the acquisition and performance of tasks of spatial working and short-term memory and sustained attention in rats. J Pharmacol Exp Ther. 2013;347:547-56 pubmed publisher

Frank G. An 11-year-old boy with Asperger's disorder presenting with aggression. Am J Psychiatry. 2013;170:963-6 pubmed publisher

Simpson H, Foa E, Liebowitz M, Huppert J, Cahill S, Maher M, et al. Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial. JAMA Psychiatry. 2013;70:1190-9 pubmed publisher

Ressler K, Rothbaum B. Augmenting obsessive-compulsive disorder treatment: from brain to mind. JAMA Psychiatry. 2013;70:1129-31 pubmed publisher

Najim H, Islam N. Checking physical care of people on risperidone long term injectable depot. Psychiatr Danub. 2013;25 Suppl 2:S171-3 pubmed

de la Fuente Sandoval C, León Ortiz P, Azcárraga M, Stephano S, Favila R, Díaz Galvis L, et al. Glutamate levels in the associative striatum before and after 4 weeks of antipsychotic treatment in first-episode psychosis: a longitudinal proton magnetic resonance spectroscopy study. JAMA Psychiatry. 2013;70:1057-66 pubmed publisher

Sanz Fuentenebro J, Taboada D, Palomo T, Aragües M, Ovejero S, Del Alamo C, et al. Randomized trial of clozapine vs. risperidone in treatment-naïve first-episode schizophrenia: results after one year. Schizophr Res. 2013;149:156-61 pubmed publisher

Roke Y, van Harten P, Franke B, Galesloot T, Boot A, Buitelaar J. The effect of the Taq1A variant in the dopamine D₂ receptor gene and common CYP2D6 alleles on prolactin levels in risperidone-treated boys. Pharmacogenet Genomics. 2013;23:487-93 pubmed publisher

Goghari V, Smith G, Honer W, Kopala L, Thornton A, Su W, et al. Effects of eight weeks of atypical antipsychotic treatment on middle frontal thickness in drug-naïve first-episode psychosis patients. Schizophr Res. 2013;149:149-55 pubmed publisher

Ghaleiha A, Mohammadi E, Mohammadi M, Farokhnia M, Modabbernia A, Yekehtaz H, et al. Riluzole as an adjunctive therapy to risperidone for the treatment of irritability in children with autistic disorder: a double-blind, placebo-controlled, randomized trial. Paediatr Drugs. 2013;15:505-14 pubmed publisher

. Risperidone: rhabdomyolysis. Prescrire Int. 2013;22:128 pubmed

Vieweg W, Hasnain M, Hancox J, Baranchuk A, Digby G, Kogut C, et al. Risperidone, QTc interval prolongation, and torsade de pointes: a systematic review of case reports. Psychopharmacology (Berl). 2013;228:515-24 pubmed publisher

Konarzewska B, Waszkiewicz N, Galińska B, Szulc A. Fasting insulin serum levels and psychopathology profiles in male schizophrenic inpatients treated with olanzapine or risperidone. Neuro Endocrinol Lett. 2013;34:322-8 pubmed

Stafford N. German insurer finds a third of people over 65 take five or more drugs a day. BMJ. 2013;346:f3905 pubmed publisher

Bachmann C, Manthey T, Kamp Becker I, Glaeske G, Hoffmann F. Psychopharmacological treatment in children and adolescents with autism spectrum disorders in Germany. Res Dev Disabil. 2013;34:2551-63 pubmed publisher

Takeuchi K, Sanjo K, Sakai A. [Paliperidone, risperidone]. Nihon Rinsho. 2013;71:654-9 pubmed

Vale T, Freitas D, Maciel R, Miranda E, Cardoso F. Teaching Video NeuroImages: hemichorea-hemiballismus secondary to nonketotic hyperglycemia. Neurology. 2013;80:e178 pubmed publisher

Moisan J, Turgeon M, Desjardins O, Grégoire J. Comparative safety of antipsychotics: another look at the risk of diabetes. Can J Psychiatry. 2013;58:218-24 pubmed

Kirk Morton N, Zubek D. Adherence challenges and long-acting injectable antipsychotic treatment in patients with schizophrenia. J Psychosoc Nurs Ment Health Serv. 2013;51:13-8 pubmed

Almandil N, Liu Y, Murray M, Besag F, Aitchison K, Wong I. Weight gain and other metabolic adverse effects associated with atypical antipsychotic treatment of children and adolescents: a systematic review and meta-analysis. Paediatr Drugs. 2013;15:139-50 pubmed publisher

Shulman M, Jennifer Njoku I, Manu P. Thrombotic complications of treatment with antipsychotic drugs. Minerva Med. 2013;104:175-84 pubmed

Wang S, Li W, Zhao J, Zhang H, Yang Y, Wang X, et al. Association of estrogen receptor alpha gene polymorphism with age at onset, general psychopathology symptoms, and therapeutic effect of schizophrenia. Behav Brain Funct. 2013;9:12 pubmed publisher

Pisano S, Gritti A, Catone G, Pascotto A. Antipsychotic-induced dyslipidemia treated with omega 3 fatty acid supplement in an 11-year-old psychotic child: a 1-year follow-up. J Child Adolesc Psychopharmacol. 2013;23:139-41 pubmed publisher

Calarge C, Ziegler E. Iron deficiency in pediatric patients in long-term risperidone treatment. J Child Adolesc Psychopharmacol. 2013;23:101-9 pubmed publisher

Bhatia M, Jhanjee A, Srivastava S. Delusional infestation: a clinical profile. Asian J Psychiatr. 2013;6:124-7 pubmed publisher

Tsuchie K, Miyaoka T, Furuya M, Liaury K, Ieda M, Wake R, et al. The effects of antipsychotics on behavioral abnormalities of the Gunn rat (unconjugated hyperbilirubinemia rat), a rat model of schizophrenia. Asian J Psychiatr. 2013;6:119-23 pubmed publisher

Cartwright A, Wilby K, Corrigan S, Ensom M. Pharmacogenetics of risperidone: a systematic review of the clinical effects of CYP2D6 polymorphisms. Ann Pharmacother. 2013;47:350-60 pubmed publisher

Khanna P, Komossa K, Rummel Kluge C, Hunger H, Schwarz S, El Sayeh H, et al. Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2013;:CD006569 pubmed publisher

Schmidt M, Sofronescu A, Short B, Nahas Z, Zhu Y. Increased prolactin concentrations in a patient with bipolar disorder. Clin Chem. 2013;59:473-5 pubmed publisher

Ghate S, Porucznik C, Said Q, Hashibe M, Joy E, Brixner D. Association between second-generation antipsychotics and changes in body mass index in adolescents. J Adolesc Health. 2013;52:336-43 pubmed publisher

Kar S, Saxena S, Trivedi J. Electroconvulsive treatment in catatonia of cerebrovasculo-coagulopathy: a case report. J ECT. 2013;29:e8-9 pubmed publisher

Gopal S, Hough D, Karcher K, Nuamah I, Palumbo J, Berlin J, et al. Risk of cardiovascular morbidity with risperidone or paliperidone treatment: analysis of 64 randomized, double-blind trials. J Clin Psychopharmacol. 2013;33:157-61 pubmed publisher

Wei Z, Wang L, Yu T, Wang Y, Sun L, Wang T, et al. Histamine H4 receptor polymorphism: a potential predictor of risperidone efficacy. J Clin Psychopharmacol. 2013;33:221-5 pubmed publisher

Shah U, Vu C, Thomas R, Hartman D, Sharma T. Alcohol-induced psychotic disorder in a 42-year-old female patient. JAAPA. 2013;26:30, 32, 36 pubmed

Rogóż Z. Effect of co-treatment with mirtazapine and risperidone in animal models of the positive symptoms of schizophrenia in mice. Pharmacol Rep. 2012;64:1567-72 pubmed

Rogóż Z, Kabziński M, Sadaj W, Rachwalska P, Gądek Michalska A. Effect of co-treatment with fluoxetine or mirtazapine and risperidone on the active behaviors and plasma corticosterone concentration in rats subjected to the forced swim test. Pharmacol Rep. 2012;64:1391-9 pubmed

Roman A, Kuśmierczyk J, Klimek E, Rogóż Z, Nalepa I. Effects of co-administration of fluoxetine and risperidone on properties of peritoneal and pleural macrophages in rats subjected to the forced swimming test. Pharmacol Rep. 2012;64:1368-80 pubmed

Kimura H, Kanahara N, Watanabe H, Iyo M. Potential treatment strategy of risperidone in long-acting injectable form for schizophrenia with dopamine supersensitivity psychosis. Schizophr Res. 2013;145:130-1 pubmed publisher

Danel C, Azaroual N, Chavaria C, Odou P, Martel B, Vaccher C. Comparative study of the complex forming ability and enantioselectivity of cyclodextrin polymers by CE and 1H NMR. Carbohydr Polym. 2013;92:2282-92 pubmed publisher

Modi D, Bhalavat R, Patterson J. Suicidal and homicidal behaviors related to dextromethorphan abuse in a middle-aged woman. J Addict Med. 2013;7:143-4 pubmed publisher

Llerena A, Berecz R, Peñas Lledó E, Süveges A, Fariñas H. Pharmacogenetics of clinical response to risperidone. Pharmacogenomics. 2013;14:177-94 pubmed publisher

Bocharov A, Kondakova V, Tuleninov E. [Efficasy and safety of the use of risperidone (rispoluxe) in demented patients with psychotic and behavioural disorders]. Zh Nevrol Psikhiatr Im S S Korsakova. 2012;112:25-31 pubmed

Manfredi G, Solfanelli A, Dimitri G, Cuomo I, Sani G, Kotzalidis G, et al. Risperidone-induced leukopenia: a case report and brief review of literature. Gen Hosp Psychiatry. 2013;35:102.e3-6 pubmed publisher

Germann D, Kurylo N, Han F. Risperidone. Profiles Drug Subst Excip Relat Methodol. 2012;37:313-61 pubmed publisher

Diem O, Schäffner M, Seifarth W, Leib Mösch C. Influence of antipsychotic drugs on human endogenous retrovirus (HERV) transcription in brain cells. PLoS ONE. 2012;7:e30054 pubmed publisher

Yang H, Cheng Y. Peripheral edema associated with risperidone oral solution: a case report and a review of the literature. J Clin Psychopharmacol. 2012;32:128-30 pubmed publisher

Duhig M, Saha S, Scott J. Efficacy of risperidone in children with disruptive behavioural disorders. J Paediatr Child Health. 2013;49:19-26 pubmed publisher

Seto K, Dumontet J, Ensom M. Risperidone in schizophrenia: is there a role for therapeutic drug monitoring?. Ther Drug Monit. 2011;33:275-83 pubmed publisher

Komossa K, Rummel Kluge C, Schwarz S, Schmid F, Hunger H, Kissling W, et al. Risperidone versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2011;:CD006626 pubmed publisher

Owenby R, Brown L, Brown J. Use of risperidone as augmentation treatment for major depressive disorder. Ann Pharmacother. 2011;45:95-100 pubmed publisher

Schmalhofer W, Swensen A, Thomas B, Felix J, Haedo R, Solly K, et al. A pharmacologically validated, high-capacity, functional thallium flux assay for the human Ether-à-go-go related gene potassium channel. Assay Drug Dev Technol. 2010;8:714-26 pubmed publisher

Soumya R, Grover S, Dutt A, Gaur N. Angioneurotic edema with risperidone: a case report and review of literature. Gen Hosp Psychiatry. 2010;32:646.e1-3 pubmed publisher

Bobo W, Shelton R. Risperidone long-acting injectable (Risperdal Consta®) for maintenance treatment in patients with bipolar disorder. Expert Rev Neurother. 2010;10:1637-58 pubmed publisher

Melnik T, Soares B, Puga M, Atallah A. Efficacy and safety of atypical antipsychotic drugs (quetiapine, risperidone, aripiprazole and paliperidone) compared with placebo or typical antipsychotic drugs for treating refractory schizophrenia: overview of systematic reviews. Sao Paulo Med J. 2010;128:141-66 pubmed

Glatstein M, Sulowski C, Waisburg C, Koren G, Garcia Bournissen F. Severe extrapiramidal symptoms after nonintentional risperidone exposure in a child: case report and review of the literature. Am J Ther. 2011;18:e271-3 pubmed publisher

Fagiolini A, Casamassima F, Mostacciuolo W, Forgione R, Goracci A, Goldstein B. Risperidone long-acting injection as monotherapy and adjunctive therapy in the maintenance treatment of bipolar I disorder. Expert Opin Pharmacother. 2010;11:1727-40 pubmed publisher

Deeks E. Risperidone long-acting injection: in bipolar I disorder. Drugs. 2010;70:1001-12 pubmed publisher

de Leon J, Wynn G, Sandson N. The pharmacokinetics of paliperidone versus risperidone. Psychosomatics. 2010;51:80-8 pubmed publisher